ÌìÃÀÓ°Ôº

CareersInvestor ÌìÃÀÓ°ÔºPress RoomCOVID-19

Siemens Healthineers Australia

Tools & Resources

New products and solutions

Keyvisual sustainable future
ÌìÃÀÓ°Ôº for Clinical Labs

Siemens Healthineers is driving transparency and accountability in clinical laboratory sustainability.Ìý

Clinical labs may operate around the clock to test patient samples whenever results are needed. Traditionally, In Vitro Diagnostic testing requires significant amounts of water, energy, and plastic consumables, placing labs among the most environmentally taxing healthcare operations

Siemens Healthineers NfL Neuron
Neurofilament Light Chain (NfL) 

A simple blood test delivering key insights into MS disease activity. Introducing NfL, the groundbreaking blood test first to be CE marked* for predicting the risk of future MS disease activity. The NfL assay is offered on the Atellica IM, Atellica CI, and ADVIA Centaur XP/XPT systems and provides fast, reproducible, novel insights into MS (Multiple Sclerosis) disease activity; from a simple blood draw using serum and plasma.†

Customer Services
Your voice matters

Customer feedback Program

Santé de la femme : formation et éducation
Education Fixture

Don't miss an education course or workshop again.

Siemens Healthineers at RSNA
Upcoming Events

Current and upcoming Siemens Healthineers Tradeshows.

Free.star VET
Veterinary Solutions

With a trusted partner in Veterinary Diagnostic Imaging and Pathology solutions.Ìý

News & Topics

Cardiac health: In great shape but close to death

"I was extremely lucky," says Frank – and it's not a visit to the casino that he's referring to. It’s a life-saving check-up. 

Ìý
Images courtesy of Siemens Healthineers Image Library
*CE 0197
†The Atellica IM NfL assay, in conjunction with clinical, imaging, and laboratory findings, is intended to be used as an aid in identifying adult patients between 18–55 years of age with Relapsing Multiple Sclerosis (RMS), who are at a higher versus lower risk of MS disease activity, as defined by new or enlarging T2 (neT2) magnetic resonance imaging (MRI) lesions, within a 2 year period.